81 results
8-K
EX-10.1
ARAV
Aravive Inc
17 Jan 24
Entry into a Material Definitive Agreement
4:22pm
to economic loss, property damage, personal injury or death in connection with, or occurring on or in the vicinity of, any assets of the assignment
8-K
EX-10.2
ARAV
Aravive Inc
11 Apr 23
Aravive Appoints Carolina Petrini as Chief Commercial Officer
7:10am
of your Continuous Service for any reason other than Cause, Disability, or death;
(c) 12 months after the termination of your Continuous Service due … to your Disability;
(d) 18 months after your death if you die during your Continuous Service;
(e) immediately upon a Corporate Transaction
8-K
EX-10.2
ARAV
Aravive Inc
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
or ceases to be a director (whether as a result of his or her death, disability, disqualification, or otherwise) the Investors shall be entitled
8-K
EX-10.1
0swp5e52y
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
gky0 hnpqhn
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
epfl0
9 Aug 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
7:09am
8-K
EX-10.1
w6df8udb vg
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
0rayqyff yapv0cj
18 May 21
Aravive Announces Three New Appointments to its Board of Directors
7:05am
8-K
EX-99.2
fxbkld56e8nf3527pd1
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
ve58jqe8vkp ka
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
qs1h 219rmyr4b0d
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
eze7mwvo02
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am